IXHL vs. CRVO, PRLD, IMAB, INCR, SKYE, RGLS, ACET, PRQR, RPTX, and DMAC
Should you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include CervoMed (CRVO), Prelude Therapeutics (PRLD), I-Mab (IMAB), InterCure (INCR), Skye Bioscience (SKYE), Regulus Therapeutics (RGLS), Adicet Bio (ACET), ProQR Therapeutics (PRQR), Repare Therapeutics (RPTX), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical preparations" industry.
Incannex Healthcare (NASDAQ:IXHL) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
In the previous week, Incannex Healthcare and Incannex Healthcare both had 4 articles in the media. CervoMed's average media sentiment score of 1.17 beat Incannex Healthcare's score of 0.51 indicating that CervoMed is being referred to more favorably in the news media.
0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 14.6% of Incannex Healthcare shares are owned by insiders. Comparatively, 2.0% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Incannex Healthcare has a beta of 8.65, suggesting that its share price is 765% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
CervoMed has higher revenue and earnings than Incannex Healthcare.
CervoMed received 3 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
CervoMed has a consensus price target of $57.50, suggesting a potential upside of 133.83%. Given CervoMed's higher possible upside, analysts clearly believe CervoMed is more favorable than Incannex Healthcare.
Incannex Healthcare's return on equity of 0.00% beat CervoMed's return on equity.
Summary
CervoMed beats Incannex Healthcare on 7 of the 12 factors compared between the two stocks.
Get Incannex Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incannex Healthcare Competitors List
Related Companies and Tools
